Healthcare
Live Price
Offline$3.72
+2.76% today
1Y Change
+23.47%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Voyager Therapeutics, Inc. (VYGR) is a Healthcare stock with a market cap of $230.00M and listed on NASDAQ. The stock last traded around $3.72 and up 23.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of -49.5%, EPS growth of -80.5%, a dividend yield of 0.0%. What stands out right now is revenue -49.5%, EPS -80.5%, free cash flow -617.2% with operating margin -326.6% and ROIC -56.4%. Valuation sits in the middle of the pack at price/sales 5.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VYGR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VYGR
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VYGR Max Drawdown
-37.71%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VYGR and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$37.4M
-8.5% YoY
FY Net Income
-$71.2M
-53.4% YoY
Free Cash Flow
-$55.1M
-267.6% YoY
Revenue Growth
-49.5%
EPS Growth
-80.5%
Gross Margin
100.0%
Net Margin
-296.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 40M | 80M | 250M | 41M | 37M |
| Gross Profit | 40M | 80M | 158M | -15M | -36M |
| Operating Income | -132M | -83M | 122M | -51M | -74M |
| EBITDA | -128M | -79M | 126M | -40M | -68M |
| Net Income | -120M | -65M | 132M | -46M | -71M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65M | 71M | 69M | 99M | 117M |
| Total Assets | 252M | 393M | 351M | 159M | 194M |
| Total Liabilities | 56M | 93M | 115M | 100M | 99M |
| Shareholder Equity | 196M | 300M | 236M | 59M | 95M |
| Total Debt | 36M | 44M | 20M | 23M | 44M |
| Net Debt | -29M | -28M | -49M | -76M | -73M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
-327.9% YoY
Capital Expenditures
2M
+35.4% YoY
Free Cash Flow
55M
-267.6% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-326.6%
Net Margin
-296.5%
ROE
-51.4%
Debt / Equity
0.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.